Antisense Therapeutics getting traction in the US, page-12

First 12 Last

Share
Profile

Follow
itsagas

13,117 Posts.

1370

03/04/22

11:59

Post #: 60608955
Share
Originally posted by Vinceanna: ↑

Mark Diamond said "In MS patients, we were able to reduce the number of new inflammatory brain lesions, we believe by reducing the CD49d protein on the T cells and keeping certain of them from going into the brain and causing more damage. MS is an autoimmune disease, with the body making antibodies against the myelin protective coating of the nerve cells in the brain, which leads to the immune cells entering the brain and the associated breakdown of the myelin.....We believe ATL1102 may have potential benefit in helping long COVID patients, particularly those with neurological symptoms. We are conducting the first study in the world to assess up to 7,000 plasma proteins in long COVID patients, looking for disease markers in the blood to identify treatments, including the potential to use ATL1102 in this condition. We expect the first results from our tests in the middle of this year."

The researchers at Northwestern medicine said they havescientific evidence that COVID-19 can createbrain inflammation, and in some cases, brain damage.

Dr. Igor Koralink said" The most noteworthy finding is that we were able to look at a marker of nerve cell damage and a marker of activation of supporting cells in the brain called 'glial cells' which are elevated in other diseases of the brain such as multiple sclerosis."

The study’s biggest findings include:
The brain is composed of neurons and a large network of supporting cells known as glial cells. This study found that combined molecular evidence of damage to neurons and activation of glial cells, indicating brain inflammation, correlated with symptoms of anxiety in COVID long-haulers.
Similar molecular findings of neuron damage and brain inflammation were detected in COVID-19 patients hospitalized at Northwestern Memorial with encephalopathy, which ranges from mild confusion to coma, and is the most severe neurologic manifestation of COVID-19.
COVID long-haulers often express frustration that they feel their neuropsychiatric symptoms are dismissed when talking about their experience, and this study’s evidence, suggesting a biological basis for these symptoms, may help to validate their experience and inform the need for further research into the mechanisms leading to these symptoms.

If ATL1102 is able to prove to treat Long Covid-19, I believe the momentum could start from here... You can rest assured that we will have more media coverage in the US...

To ANP shareholders here, is holding ANP share a blessing or curse to you? Well, it's all depends on each individual perspective.

Expand

Good post V
This to reassure the people that Atl1102 is a blockbuster drug that will give holders $5 in time.

https://med.stanford.edu/news/all-news/2021/06/signs-of-inflammation-in-brains-of-people-who-died-of-covid-19.html
ANP Price at posting: 12.5¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

Shekel Brainweigh and Calmer Co lead innovations in the retail space

RCE

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

ARN

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

There are more pages in this discussion • 73 more messages in this thread...

First 12 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.0¢		Change 0.000(0.00%)		Mkt cap ! $72.12M

Open	High	Low	Value	Volume
8.1¢	8.1¢	7.9¢	$33.53K	416.4K

Buyers (Bids)

No.	Vol.	Price($)
2	92000	7.9¢

Sellers (Offers)

Price($)	Vol.	No.
8.0¢	65186	3

View Market Depth

No.	Vol.	Price($)
2	92000	0.079
2	212658	0.078
1	200000	0.077
2	66500	0.076
4	206988	0.075

Price($)	Vol.	No.
0.080	65186	3
0.082	97561	1
0.083	214000	1
0.084	161142	2
0.085	141000	2

Last trade - 16.10pm 15/07/2024 (20 minute delay)

PER (ASX) Chart

Antisense Therapeutics getting traction in the US, page-12

Shekel Brainweigh and Calmer Co lead innovations in the retail space

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Antisense Therapeutics getting traction in the US, page-12

Top Stories

Shekel Brainweigh and Calmer Co lead innovations in the retail space

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News